Age-related macular degeneration (AMD) is the most common form of irreversible blindness in the world, affecting 50 million people with direct costs of $255 billion in the United States annually. Approximately 25% of people over 80 years of age suffer from this condition.
In dry AMD and geographic atrophy, a more advanced form of the disease, cellular processes within retinal pigment epithelial (RPE) cells are damaged. These cells are then unable to perform their critical role in maintaining healthy photoreceptors, which are necessary for vision. As the disease progresses, loss of retinal cells results in permanent vision loss known as geographic atrophy (GA).
Approved therapies for geographic atrophy secondary to AMD involve an ongoing series of injections directly to the back of the eye (intravitreal injection). Any injection into the eye carries risk of choroidal neovascularization (CNV), an abnormal growth of new blood vessels below the retina which can rupture and leak, further compromising vision.
Unlike injections that are administered to one eye per treatment cycle, an oral treatment like CT1812 has the potential to reduce the time and burden of treatment sessions with a bilateral treatment that reaches both eyes simultaneously.
The company is testing whether CT1812 has a beneficial effect on the retinal damage-response processes through its MAGNIFY Phase 2 clinical trial for patients with geographic atrophy with dry AMD.
- It has been demonstrated in animal models that oral CT1812 is delivered to the eye in quantities believed to be therapeutic.
- Cognition is currently assessing the pharmacokinetics and behavioral characteristics of CT1812.